TORC Stock Pops on Morgan Stanley Stake

The security is still off over 80% for the year, however

Lillian Currens

Digital Content Manager

Dec 31, 2019 at 9:14 AM

TORC

Pharmaceutical concern resTORbio Inc. (NASDAQ:TORC) is eyeing its biggest one-day percentage gain in over a month this morning, following news that Morgan Stanley took an 8.8% passive stake in the company. The stock is up 10.5% ahead of the bell in response, set to break out above recent consolation near the $1.25 area.

Prior to a mid-November bear gap, TORC was trading right above the $8 level. However, a surprise halt in its late-stage respiratory illness study sent resTORbio straight into penny stock territory. Since then, the stock has managed to find a floor at its $1.10 region, and is headed into its second day north of it 30-day moving average in over a month. TORC still has a ways to go though, down 83.4% for the year.

Sentiment among the brokerage bunch is understandably cautious. Five of the six covering the stock say "hold," while one analyst says "sell." The consensus 12-month price target sits at $2 -- a 31% premium to Monday's closing perch at $1.34.

Lastly, the security has been drifting around oversold territory since its massive sell off -- it's 14-day Relative Strength Index (RSI) closed last night right near the 30 level. While TORC is still right on the cusp of being oversold, a short term bounce could be in the cards for the equity.

Follow @Schaeffers

The $25K Day Trading Barrier is Gone

The long-standing Pattern Day Trader (PDT) rule that required many traders to maintain a $25,000 account balance is no longer standing in the way.

That means more traders can actively pursue short-term opportunities without the barrier that kept so many on the sidelines.

Now it's all about having the right strategy.

Dynamite Day Trading Signals helps you hit the ground running with up 2 options trade alerts per week, built to capture fast-moving opportunities.

👉 Sign up now to receive the next trade